Table 1. Data on 117 Anti-HCV Patients... | American Society of Hematology

Table 1.

Data on 117 Anti-HCV⁺ Patients Regarding Markers of HBV and HDV Infection

	Anti-HCV⁺	Anti–HCV-HBV⁺	Anti–HCV-HBV-HDV⁺
No. of patients	88	20	9
M/F	54/34	11/9	5/4
LL/ST	55/33	11/9	8/1
(%)	(62.5/37.5)	(55/45)	(89/11)
Median age^*	18.4	23.3	21.9
(mean; range)	(18.8; 6.5-30.8)	(24.2; 13.4-32.6)	(22.1; 17.4-24.1)
Median follow-up^*	13.5	18.2	17.8
(mean; range)	(13.2; 5.2-22.5)	(17.8; 12-24.8)	(17.3; 14.2-19.2)
Prior BT (yes/no)	67/21	15/5	9/0
(% yes)	(76%)	(75)	(100)
Median BT units^†	4	3	3
(mean; range)	(9.5; 0-43)	(5; 0-24)	(4; 1-9)

	Anti-HCV⁺	Anti–HCV-HBV⁺	Anti–HCV-HBV-HDV⁺
No. of patients	88	20	9
M/F	54/34	11/9	5/4
LL/ST	55/33	11/9	8/1
(%)	(62.5/37.5)	(55/45)	(89/11)
Median age^*	18.4	23.3	21.9
(mean; range)	(18.8; 6.5-30.8)	(24.2; 13.4-32.6)	(22.1; 17.4-24.1)
Median follow-up^*	13.5	18.2	17.8
(mean; range)	(13.2; 5.2-22.5)	(17.8; 12-24.8)	(17.3; 14.2-19.2)
Prior BT (yes/no)	67/21	15/5	9/0
(% yes)	(76%)	(75)	(100)
Median BT units^†	4	3	3
(mean; range)	(9.5; 0-43)	(5; 0-24)	(4; 1-9)

Abbreviations: ⁺, seropositive; M, male; F, female; LL, leukemia/lymphoma; ST, solid tumor; BT, blood transfusions.

In years, as of August 1995.

Quantity of RBCs and/or platelets transfused.